Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AbbVie Inc, Bristol Myers Squibb, and Takeda Pharmaceuticals U.S.A., Inc.

Patient, Provider & Caregiver Connection™: Optimizing Care in Inflammatory Bowel Disease – Understanding the Patient Journey and the Role of Individualized Treatment

Release Date: July 29, 2021
Expiration Date: July 29, 2022

Activity Overview

This video-based program is designed for health care professionals to explore the diagnosis and treatment of inflammatory bowel disease (IBD) through a unique perspective, putting the patient voice front and center. A patient and their caregiver will lend their expertise to this program by sharing their journey living with IBD. This online activity focuses on the disease pathophysiology, clinical presentation, diagnostic approach, efficacy and safety data of available therapies, and best practices for treatment of IBD.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc, Bristol Myers Squibb, and Takeda Pharmaceuticals U.S.A., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward gastroenterologists, primary care clinicians, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with IBD.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe clinical and diagnostic features of IBD
  • Identify difficulties and challenges in diagnosing and differentiating IBD from other disease processes
  • Select approved biologic and non-biologic agents targeting IBD based on current clinical evidence
  • Evaluate the efficacy and safety of emerging biologic therapies in patients with IBD
  • Discuss the physical and emotional burden of the patient journey during long-term management of IBD

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Bruce Sands, MD, MS
Bruce Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Mount Sinai Health System
New York, NY

Disclosures: Consultant: Abivax SA, Arena Pharmaceuticals, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Cowen Services Company, Genentech, Gilead Sciences, GlaxoSmithKline, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Janssen Biotech, Janssen Pharmaceutica NV, Kallyope, Lilly, Pfizer, Prometheus Biosciences, Protagonist Therapeutics, Surrozen, Takeda, Takeda International, Takeda Distribuidora, Target RWE, USWM Enterprises, Viela Bio; Other: Inotrem.

Anita Afzali, MD, MPH, FACG, AGAF
Anita Afzali, MD, MPH, FACG, AGAF
Associate Professor of Medicine
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Medical Director, OSU Inflammatory Bowel Disease Center
Program Director, OSU Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Columbus, OH

Disclosures: Consultant: AbbVie, Bristol Myers Squibb, DiaSorin, Gilead, Janssen, Lilly, Pfizer, Takeda, TLL Pharmaceutical; Speaker’s Bureau: AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda; Other: (Founder and Board Member) IBD Horizons.

Zachary Sloan

Disclosures: Zachary Sloan has no relevant financial relationships with ineligible companies.

Brena Resnick

Disclosures: Brena Resnick has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By